Key Takeaways
- Amoéba and Syngenta have signed an MoU to co-develop an amoeba-derived bio-fungicide for the EU and UK cereal markets.
- The biological solution, based on Willaertia magna C2c Maky lysate, targets major wheat diseases including STB and yellow rust.
- Initial trials show strong efficacy and activation of plant defence responses.
- Amoéba’s active substance received EU approval in June 2025, with product authorizations underway.
- A definitive distribution agreement is expected by spring 2026.
Amoéba Advances Collaboration with Syngenta on New Biological Fungicide
Amoéba, the French greentech innovator behind a patented amoeba-based biocontrol technology, has entered a Memorandum of Understanding with Syngenta Crop Protection to develop and commercialize a next-generation biological fungicide for cereals and other field crops across the EU and UK. The initiative builds on growing demand for sustainable tools as farmers face rising disease pressure and a shrinking portfolio of crop protection options.
The candidate product, derived from the lysate of Willaertia magna C2c Maky, has shown strong performance against key fungal pathogens in trials and supports integrated crop management.
Amoéba Technology Targets Major Wheat Diseases Across Europe
The partnership will initially focus on septoria tritici blotch (STB) and yellow rust, two of the most damaging wheat diseases across Europe and the UK, affecting an estimated 9–12 million hectares annually. In Germany alone, STB contributes to up to €1.5 billion in losses each year.
According to Syngenta’s Head of Seedcare and Biologicals for Europe, Matthew Pickard, the collaboration reflects the company’s aim to deliver effective, cutting-edge biological solutions. Leaders from Amoéba, including Chairman Benoit Villers and CEO Jean-François Doucet, described the partnership as a major step forward that combines both companies’ strengths to support farmers and expand biocontrol applications.
Strengthens Market Pathway Following EU Approval
Founded in 2010, Amoéba has developed an award-winning biocontrol technology based on its Willaertia magna lysate, earning the Bernard Blum Gold Medal in 2025. The company’s active substance gained EU approval in June 2025 following EFSA’s scientific assessment, and product-level authorizations are progressing.
Amoéba’s collaboration with Syngenta aims to deliver viable biological alternatives that address rising resistance, support sustainability goals, and provide effective disease control for growers.
